- Allergan said on Tuesday that the Food and Drug Administration would not approve one of its women’s health drugs, Esmya.
- The drug was being investigated to treat uterine fibroids, a condition characterised by benign tumours that grow in and around the uterus that can cause heavy bleeding and pain.
- The agency cited “safety concerns regarding Esmya post-marketing reports outside the United States,” Allergan said. The drug is available in Europe, but European regulators have raised concerns about the risk of a “rare but serious liver injury” in women taking the drug.
- Allergan said in May that it was planning to sell off its women’s-health and infectious-disease businesses, which it considered noncore to the company.
- “While this is another setback, we believe investors will likely not be disturbed by this,” Wells Fargo analyst David Maris said in a note Wednesday.
- The stock was down as much as 1.5% in pre-market trading Wednesday on the news.
NOW WATCH: Briefing videos
Business Insider Emails & Alerts
Site highlights each day to your inbox.